What is HC Wainwright's Estimate for ATOS FY2026 Earnings?

Atossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) - Equities researchers at HC Wainwright reduced their FY2026 EPS estimates for shares of Atossa Therapeutics in a research report issued on Wednesday, November 13th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.32) per share for the year, down from their prior forecast of ($0.21). HC Wainwright currently has a "Buy" rating and a $7.00 target price on the stock. The consensus estimate for Atossa Therapeutics' current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Atossa Therapeutics' FY2027 earnings at ($0.27) EPS and FY2028 earnings at ($0.21) EPS.

ATOS has been the topic of several other reports. StockNews.com downgraded shares of Atossa Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, November 8th. Ascendiant Capital Markets raised their price target on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the company a "buy" rating in a report on Wednesday, September 11th.

Atossa Therapeutics Stock Down 6.6 %

Shares of NASDAQ:ATOS traded down $0.09 during midday trading on Friday, reaching $1.28. 1,325,572 shares of the company traded hands, compared to its average volume of 1,077,866. The firm's fifty day moving average price is $1.44 and its two-hundred day moving average price is $1.38. The firm has a market capitalization of $160.97 million, a price-to-earnings ratio of -5.86 and a beta of 1.23. Atossa Therapeutics has a 12 month low of $0.65 and a 12 month high of $2.31.

Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) last posted its earnings results on Monday, August 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01.

Institutional Investors Weigh In On Atossa Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp lifted its stake in Atossa Therapeutics by 3,160.5% during the second quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company's stock worth $490,000 after purchasing an additional 399,041 shares during the last quarter. Cetera Advisors LLC bought a new stake in Atossa Therapeutics in the 1st quarter worth approximately $72,000. Virtu Financial LLC bought a new stake in Atossa Therapeutics in the 1st quarter worth approximately $151,000. Rhumbline Advisers purchased a new stake in Atossa Therapeutics in the second quarter worth approximately $161,000. Finally, Vanguard Group Inc. grew its position in Atossa Therapeutics by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company's stock valued at $10,357,000 after acquiring an additional 78,269 shares during the last quarter. 12.74% of the stock is owned by hedge funds and other institutional investors.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.